Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM.

J Immunother Cancer. 2019 Mar 12;7(1):70. doi: 10.1186/s40425-019-0538-8.

2.

Surface-Induced Dissociation of Noncovalent Protein Complexes in an Extended Mass Range Orbitrap Mass Spectrometer.

VanAernum ZL, Gilbert JD, Belov ME, Makarov AA, Horning SR, Wysocki VH.

Anal Chem. 2019 Mar 5;91(5):3611-3618. doi: 10.1021/acs.analchem.8b05605. Epub 2019 Feb 12.

PMID:
30688442
3.

The 3D OrbiSIMS-label-free metabolic imaging with subcellular lateral resolution and high mass-resolving power.

Passarelli MK, Pirkl A, Moellers R, Grinfeld D, Kollmer F, Havelund R, Newman CF, Marshall PS, Arlinghaus H, Alexander MR, West A, Horning S, Niehuis E, Makarov A, Dollery CT, Gilmore IS.

Nat Methods. 2017 Dec;14(12):1175-1183. doi: 10.1038/nmeth.4504. Epub 2017 Nov 13.

PMID:
29131162
4.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM.

Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13.

5.

A new cancer ecosystem.

Horning SJ.

Science. 2017 Mar 17;355(6330):1103. doi: 10.1126/science.aan1295. No abstract available.

PMID:
28302798
6.

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS.

Leukemia. 2017 Feb;31(2):517-519. doi: 10.1038/leu.2016.305. Epub 2016 Oct 26. No abstract available.

7.

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).

Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS.

Cancer. 2016 Oct;122(19):2996-3004. doi: 10.1002/cncr.30137. Epub 2016 Jun 28.

8.

Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.

Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS.

Br J Haematol. 2016 Jun;173(6):867-75. doi: 10.1111/bjh.14007. Epub 2016 Mar 11.

9.

An informatic framework for decoding protein complexes by top-down mass spectrometry.

Skinner OS, Havugimana PC, Haverland NA, Fornelli L, Early BP, Greer JB, Fellers RT, Durbin KR, Do Vale LH, Melani RD, Seckler HS, Nelp MT, Belov ME, Horning SR, Makarov AA, LeDuc RD, Bandarian V, Compton PD, Kelleher NL.

Nat Methods. 2016 Mar;13(3):237-40. doi: 10.1038/nmeth.3731. Epub 2016 Jan 18.

10.

Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.

Kenkre VP, Hong F, Cerhan JR, Lewis M, Sullivan L, Williams ME, Gascoyne RD, Horning SJ, Kahl BS.

Clin Cancer Res. 2016 Feb 15;22(4):821-6. doi: 10.1158/1078-0432.CCR-15-1848. Epub 2015 Oct 28.

11.

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH.

Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7.

12.

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.

Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H Jr, Kahl BS, Advani RH, Horning SJ.

Br J Haematol. 2015 Sep;170(5):679-86. doi: 10.1111/bjh.13493. Epub 2015 May 14.

13.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.

J Clin Oncol. 2015 Jun 10;33(17):1936-42. doi: 10.1200/JCO.2014.57.8138. Epub 2015 Apr 20.

14.

Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).

Swinnen LJ, Li H, Quon A, Gascoyne R, Hong F, Ranheim EA, Habermann TM, Kahl BS, Horning SJ, Advani RH.

Br J Haematol. 2015 Jul;170(1):56-65. doi: 10.1111/bjh.13389. Epub 2015 Mar 30.

15.

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS.

J Clin Oncol. 2015 Mar 1;33(7):740-8. doi: 10.1200/JCO.2014.57.6801. Epub 2015 Jan 20.

16.

Patient priority in the era of patent expiries.

Horning S.

Lancet Oncol. 2014 Oct;15(11):e474. doi: 10.1016/S1470-2045(14)70470-X. No abstract available.

PMID:
25281466
17.

Development of a GC/Quadrupole-Orbitrap mass spectrometer, part I: design and characterization.

Peterson AC, Hauschild JP, Quarmby ST, Krumwiede D, Lange O, Lemke RA, Grosse-Coosmann F, Horning S, Donohue TJ, Westphall MS, Coon JJ, Griep-Raming J.

Anal Chem. 2014 Oct 21;86(20):10036-43. doi: 10.1021/ac5014767. Epub 2014 Sep 10.

18.

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ.

J Clin Oncol. 2014 Oct 1;32(28):3096-102. doi: 10.1200/JCO.2014.56.5853. Epub 2014 Aug 25.

19.

I am pregnant and want to do better but i can't: focus groups with low-income overweight and obese pregnant women.

Chang MW, Nitzke S, Buist D, Cain D, Horning S, Eghtedary K.

Matern Child Health J. 2015 May;19(5):1060-70. doi: 10.1007/s10995-014-1605-x.

PMID:
25115522
20.

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS.

Ann Oncol. 2014 Mar;25(3):669-74. doi: 10.1093/annonc/mdt594.

21.

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL.

J Clin Oncol. 2014 Mar 20;32(9):912-8. doi: 10.1200/JCO.2013.53.2069. Epub 2014 Feb 10.

PMID:
24516013
22.

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

Chang JE, Li H, Smith MR, Gascoyne RD, Paietta EM, Yang DT, Advani RH, Horning SJ, Kahl BS.

Blood. 2014 Mar 13;123(11):1665-73. doi: 10.1182/blood-2013-08-523845. Epub 2014 Jan 23.

23.

Novel parallelized quadrupole/linear ion trap/Orbitrap tribrid mass spectrometer improving proteome coverage and peptide identification rates.

Senko MW, Remes PM, Canterbury JD, Mathur R, Song Q, Eliuk SM, Mullen C, Earley L, Hardman M, Blethrow JD, Bui H, Specht A, Lange O, Denisov E, Makarov A, Horning S, Zabrouskov V.

Anal Chem. 2013 Dec 17;85(24):11710-4. doi: 10.1021/ac403115c. Epub 2013 Nov 27.

PMID:
24251866
24.

From protein complexes to subunit backbone fragments: a multi-stage approach to native mass spectrometry.

Belov ME, Damoc E, Denisov E, Compton PD, Horning S, Makarov AA, Kelleher NL.

Anal Chem. 2013 Dec 3;85(23):11163-73. doi: 10.1021/ac4029328. Epub 2013 Nov 20.

PMID:
24237199
25.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM; Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).

Ann Oncol. 2013 Dec;24(12):3065-9. doi: 10.1093/annonc/mdt389. Epub 2013 Oct 11.

PMID:
24121121
26.

Hydrogen isotope ratio mass spectrometry and high-resolution/high-accuracy mass spectrometry in metabolite identification studies: detecting target compounds for sports drug testing.

Thevis M, Piper T, Horning S, Juchelka D, Schänzer W.

Rapid Commun Mass Spectrom. 2013 Sep 15;27(17):1904-12. doi: 10.1002/rcm.6648.

27.

A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).

Greenwald DR, Li H, Luger SM, Go RS, King D, Patel T, Gascoyne RD, Kolesar J, Kahl BS, Horning S.

J Hematol Oncol. 2013 Jul 5;6:46. doi: 10.1186/1756-8722-6-46.

28.

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).

Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH.

Leuk Lymphoma. 2014 Apr;55(4):768-72. doi: 10.3109/10428194.2013.816700. Epub 2013 Jul 29.

29.

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH.

Blood. 2013 Aug 8;122(6):981-7. doi: 10.1182/blood-2013-03-491514. Epub 2013 Jun 18.

30.

Developing standards for breakthrough therapy designation in oncology.

Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL.

Clin Cancer Res. 2013 Aug 15;19(16):4297-304. doi: 10.1158/1078-0432.CCR-13-0523. Epub 2013 May 29.

31.

Insight in Alzheimer's disease and its relation to psychiatric and behavioral disturbances.

Horning SM, Melrose R, Sultzer D.

Int J Geriatr Psychiatry. 2014 Jan;29(1):77-84. doi: 10.1002/gps.3972. Epub 2013 May 14.

32.

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.

Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, Younes A, Morschhauser F, McMillan A, Horning SJ.

Leuk Lymphoma. 2013 Nov;54(11):2531-3. doi: 10.3109/10428194.2013.798868. Epub 2013 Jun 5. No abstract available.

PMID:
23617324
33.

Utility of the SLUMS as a cognitive screening tool among a nonveteran sample of older adults.

Feliciano L, Horning SM, Klebe KJ, Anderson SL, Cornwell RE, Davis HP.

Am J Geriatr Psychiatry. 2013 Jul;21(7):623-30. doi: 10.1016/j.jagp.2013.01.024. Epub 2013 Feb 6.

PMID:
23567386
34.

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF.

Blood. 2013 May 2;121(18):3547-53. doi: 10.1182/blood-2012-09-454694. Epub 2013 Feb 5.

35.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ.

Br J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29.

36.

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.

Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH.

J Clin Oncol. 2013 Feb 10;31(5):592-8. doi: 10.1200/JCO.2012.44.5791. Epub 2013 Jan 7.

37.

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.

J Clin Oncol. 2013 Feb 20;31(6):684-91. doi: 10.1200/JCO.2012.43.4803. Epub 2012 Nov 26.

38.

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD.

J Clin Oncol. 2013 Feb 20;31(6):692-700. doi: 10.1200/JCO.2012.43.4589. Epub 2012 Nov 26.

39.

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.

Advani RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J, Daadi S, Rosenberg SA, Horning SJ.

Ann Oncol. 2013 Apr;24(4):1044-8. doi: 10.1093/annonc/mds542. Epub 2012 Nov 7.

40.

Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.

Minn AY, Riedel E, Halpern J, Johnston LJ, Horning SJ, Hoppe RT, Goodman KA.

Br J Haematol. 2012 Nov;159(3):329-39. doi: 10.1111/bjh.12038. Epub 2012 Sep 12.

PMID:
22966754
41.

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD.

Blood. 2012 Oct 18;120(16):3280-7. doi: 10.1182/blood-2012-04-421057. Epub 2012 Sep 4.

42.

Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.

Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ.

J Clin Oncol. 2012 Sep 1;30(25):3119-26. doi: 10.1200/JCO.2012.42.2444. Epub 2012 Jul 30.

43.

Age effects on emotion recognition in facial displays: from 20 to 89 years of age.

West JT, Horning SM, Klebe KJ, Foster SM, Cornwell RE, Perrett D, Burt DM, Davis HP.

Exp Aging Res. 2012;38(2):146-68. doi: 10.1080/0361073X.2012.659997.

PMID:
22404538
44.

The recognition of facial expressions: an investigation of the influence of age and cognition.

Horning SM, Cornwell RE, Davis HP.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2012 Nov;19(6):657-76. doi: 10.1080/13825585.2011.645011. Epub 2012 Feb 28.

PMID:
22372982
45.

Advancing cell biology through proteomics in space and time (PROSPECTS).

Lamond AI, Uhlen M, Horning S, Makarov A, Robinson CV, Serrano L, Hartl FU, Baumeister W, Werenskiold AK, Andersen JS, Vorm O, Linial M, Aebersold R, Mann M.

Mol Cell Proteomics. 2012 Mar;11(3):O112.017731. doi: 10.1074/mcp.O112.017731. Epub 2012 Feb 6.

46.

Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, Quon A, Graves EE, Loo BW Jr, Tran PT.

Radiat Oncol. 2012 Jan 19;7:5. doi: 10.1186/1748-717X-7-5.

47.

Ultra high resolution linear ion trap Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes.

Michalski A, Damoc E, Lange O, Denisov E, Nolting D, Müller M, Viner R, Schwartz J, Remes P, Belford M, Dunyach JJ, Cox J, Horning S, Mann M, Makarov A.

Mol Cell Proteomics. 2012 Mar;11(3):O111.013698. doi: 10.1074/mcp.O111.013698. Epub 2011 Dec 9.

48.

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group.

N Engl J Med. 2012 Feb 2;366(5):399-408. doi: 10.1056/NEJMoa1111961. Epub 2011 Dec 11.

49.

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

Wiernik PH, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon LI, Habermann TM, Minniti CJ Jr, Shapiro GR, Cassileth PA.

Leuk Lymphoma. 2012 Jun;53(6):1137-42. doi: 10.3109/10428194.2011.643406. Epub 2012 Jan 11.

50.

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.

Advani RH, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K.

Leuk Lymphoma. 2012 Apr;53(4):718-20. doi: 10.3109/10428194.2011.623256. Epub 2011 Dec 5. No abstract available.

Supplemental Content

Loading ...
Support Center